Search Bar & Filters
Found 40 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of TQB2102 for injection compared to a standard drug regimen in the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer. This phase III randomized, open-label, multi-center trial involves about 544 patients who will be assigned to receive either TQB2102 or a combination of Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin. The study aims to assess key outcomes such as total physiological complete response tpCR, breast pathological complete response bpCR, objective response rate ORR, event-free survival EFS, invasive disease-free survival IDFS, overall survival OS, and safety indicators including adverse events and immune response markers. Participants in the TQB2102 group will receive 8 cycles of intravenous infusion every 3 weeks, each cycle lasting 21 days. The comparator group will receive 6 cycles of a combination treatment with Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin, also administered intravenously every 3 weeks for 21-day cycles. After completing the assigned treatment cycles, all participants will undergo breast cancer surgery. Following surgery, there will be visits to monitor disease recurrence and overall survival. Throughout the study, participants will be closely monitored with evaluations conducted up to 50 months after study start. These include assessments of tumor response by independent review and investigators, safety monitoring from consent through 40 days post last dosing or surgery, and testing for anti-drug and neutralizing antibodies. Participants will have scheduled visits for treatment administration, surgery, and follow-up to track outcomes and safety over several years.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the use of multimodal ultrasound to assess muscle mass in people with metabolic diseases such as metabolic syndrome, type 2 diabetes, and simple obesity. Muscle mass reduction is common in these conditions and is linked to insulin resistance and complications. Current muscle assessment methods like DXA, CT, and MRI have drawbacks including high cost, radiation exposure, or limited portability, making them less suitable for routine use. The study will include 320 participants divided into four groups metabolic syndrome, type 2 diabetes, simple obesity, and healthy controls. Each participant will undergo baseline clinical data collection, biochemical tests, muscle function tests handgrip strength, gait speed, SPPB, multimodal ultrasound examinations measuring muscle morphology, stiffness, microcirculation, and DXA scans as a standard reference. The metabolic disease groups will have follow-up assessments at 6 and 12 months. Participants will be assessed using clinical exams, blood tests, muscle function evaluations, and advanced ultrasound imaging performed by trained sonographers. Researchers will analyze ultrasound parameters to identify diagnostic thresholds for metabolic sarcopenia, correlate these with metabolic indicators, and develop combined diagnostic models. The study will also evaluate how baseline ultrasound findings predict disease progression and complications over 12 months, aiming to provide a convenient, non-invasive tool for muscle assessment in metabolic disease management.
Actively Recruiting
Researchers are conducting a prospective, multicenter, observational registry study to better understand treatment approaches, clinical practice changes, and cardiorenal risk outcomes in Chinese patients with chronic kidney disease CKD. This study aims to collect real-world data from about 3000 participants across various hospital types and geographic regions in China, reflecting diverse clinical care settings. Participants diagnosed with CKD will be enrolled and followed for up to 96 weeks. Data will be gathered at multiple sites including top-tier tertiary hospitals, regional medical centers, and secondary hospitals. Information will be collected from medical records and entered into a cloud-based electronic system to ensure quality and accuracy. The study does not involve administering treatments but observes existing clinical practices. During the study, investigators will monitor clinical indicators and outcomes related to CKD and associated conditions such as hypertension, heart failure, and hyperkalemia over the 96-week period. Medication use and changes in treatment strategies will be tracked. Participants will provide informed consent before enrollment and their health data will be regularly reviewed to assess long-term outcomes and treatment patterns.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating AK112, a PD-1VEGF bispecific antibody, as a consolidation treatment for patients with limited stage small cell lung cancer who have not shown disease progression after concurrent chemoradiation therapy. This phase III, randomized, double-blind study aims to compare the effectiveness and safety of AK112 against a placebo in this specific patient group. Participants will receive either AK112 or a placebo intravenously every three weeks as consolidation therapy following their initial chemoradiation. The study includes two groups one receiving AK112 at a dose of 20 mgkg every three weeks, and the other receiving a matching placebo on the same schedule. Treatment continues under close monitoring to assess outcomes. Throughout the study, participants will undergo regular assessments including scans and evaluations to monitor progression-free survival and overall survival over approximately six years. Additional outcome measures include response rates and disease control rates assessed by both independent review and investigators, along with safety monitoring for adverse events. This long-term follow-up helps researchers understand how the treatments perform and their impact on patient health.
Actively Recruiting
Researchers are evaluating AZD0292, a bispecific IgG1k monoclonal antibody, for preventing exacerbations in patients with bronchiectasis who are chronically colonized with Pseudomonas aeruginosa PsA. This Phase II study focuses on Chinese adults with non-cystic fibrosis bronchiectasis and frequent lung flare-ups due to persistent PsA infection, which affects lung function, quality of life, and survival. Participants receive either AZD0292 or a placebo administered intravenously starting on Day 1, with additional doses given according to the study schedule. The trial compares the safety, effectiveness, and how the body processes AZD0292 versus placebo over a treatment period lasting between 28 and 52 weeks. Throughout the study, participants undergo regular assessments including lung function tests, quality of life questionnaires, and blood tests to measure drug levels and immune responses. Researchers monitor the number of lung exacerbations and any adverse events during treatment and for up to 24 weeks after the last dose. The total participation period can extend beyond one year to capture these outcomes and ensure participant safety.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the use of pegmolesatide, a long-acting erythropoiesis-stimulating agent ESA, in patients with renal anemia who are currently treated with hypoxia-inducible factor prolyl hydroxylase inhibitors HIF-PHIs. This trial aims to explore the safety and effectiveness of switching from HIF-PHIs to pegmolesatide, addressing the current need for longer-acting and safe medications. The study is a multi-center, prospective, open-label, randomized parallel-controlled trial enrolling 96 dialysis chronic kidney disease patients with anemia. Participants are divided into two groups based on their current weekly Roxadustat dose a low-dose cohort 210 mg and a high-dose cohort >210 mg and 360 mg. Within each cohort, patients are randomly assigned to receive pegmolesatide at different initial doses 2 mg, 4 mg, or 6 mg administered subcutaneously once every 4 weeks. The dose may be adjusted according to the drugs instructions. The treatment period lasts 12 weeks, followed by a 16-week follow-up period. During the study, researchers will monitor hemoglobin levels and other blood parameters at various intervals to assess the effects of pegmolesatide. Patients will undergo assessments including hemoglobin tests, red blood cell counts, and safety monitoring for adverse events. The primary measurement is the change in mean hemoglobin levels from baseline to 12 and 16 weeks. The total participation time for each patient is 28 weeks, including treatment and follow-up.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and how the body processes a drug called YL201 when combined with Toripalimab, either with or without Cisplatin, in adults with recurrent or metastatic nasopharyngeal carcinoma. This open-label Phase IbII trial is conducted across multiple centers in China and focuses on patients whose cancer cannot be cured with local treatment. The study aims to better understand treatment effects in this advanced cancer setting. Treatment involves two groups one receiving YL201 plus Toripalimab and another receiving YL201 plus Toripalimab and Cisplatin. All study drugs are given by intravenous infusion. The trial includes a dose exploration phase to assess safety and efficacy of these combinations. Participants receive treatment according to randomized assignment to one of these regimens. Participants will be monitored for side effects, cancer progression, and response to treatment over about 36 months. Researchers will assess dose-limiting toxicities, treatment-emergent adverse events, progression-free survival, and other measures such as response rate and overall survival. The study also evaluates how YL201 and its metabolites behave in the body. Participants will undergo regular medical exams, imaging, and lab tests during the study period to track outcomes and safety.
Actively Recruiting
Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.
Actively Recruiting
Researchers are evaluating the efficacy and safety of a combination budesonide and albuterol metered dose inhaler BDA MDI compared with an albuterol sulfate AS metered dose inhaler in symptomatic Chinese adults with asthma. This randomized, double-blind, Phase III study aims to reduce the risk of severe asthma exacerbations in participants who have had asthma diagnosed for at least 12 months and currently use maintenance therapies. The study involves about 1000 eligible participants randomly assigned to receive either BDA MDI 160180 mcg delivered as two actuations of 8090 mcg or AS MDI 180 mcg delivered as two actuations of 90 mcg. Both treatments are used as needed for asthma symptoms or before exercise. The trial includes a screening period lasting 14 to 28 days, followed by a treatment period of at least 24 weeks and up to 52 weeks, and concludes with a safety follow-up about two weeks after the last treatment visit. Participants will be assessed through various visits during the study, including evaluations of lung function, asthma control questionnaires ACQ-5 and ACQ-7, and monitoring of severe asthma exacerbations. The primary outcome is the time to the first severe asthma exacerbation over the treatment period. Secondary outcomes include the rate of exacerbations, steroid exposure, and patient-reported measures of asthma control and quality of life. Safety and adherence are closely monitored throughout the study duration.
1-10 of 40
1